FDA Reclassifies Melanoma Detection Devices to Class II: What It Means for You

Last updated: 2026-04-05

The FDA has issued a landmark final order reclassifying two categories of skin lesion diagnostic devices — optical diagnostic devices for melanoma detection (product code OYD) and electrical impedance spectrometers (product code ONV) — from Class III (highest risk, PMA-required) down to Class II (moderate risk, 510(k)-required). Published in the Federal Register on March 25, 2026 (Docket No. 2026-05772), this reclassification carries immediate strategic and regulatory implications for manufacturers, clinical users, and investors in the dermatology and digital diagnostics space.

If your organization makes, distributes, or plans to develop a software-assisted skin lesion diagnostic tool, this final order changes your regulatory pathway — and your timeline. Here's what changed, why it matters, and exactly what you need to do next.

---

What the FDA Reclassified — and Why It Matters

The Two Device Types Affected

The final order covers:

1. Optical Diagnostic Devices for Melanoma Detection (OYD) — devices that use optical technologies such as dermoscopy, reflectance confocal microscopy, or spectroscopic analysis to identify suspicious pigmented skin lesions potentially indicative of melanoma.
2. Electrical Impedance Spectrometers (ONV) — devices that measure the electrical impedance of skin tissue to differentiate between malignant and benign lesions.

Both device types were previously classified as postamendments Class III, meaning manufacturers faced the most burdensome regulatory pathway: full Premarket Approval (PMA). PMAs are notoriously time-consuming and expensive — the average PMA review cycle takes 180 days of FDA review time alone, with total timelines often stretching 3–5 years when factoring in preparation and clinical study requirements.

The New Classification: Class II with Special Controls

Under this final order, both device types are reclassified into Class II and are now subject to premarket notification (510(k)) rather than PMA. Critically, FDA is also renaming and codifying these devices under a new, unified classification regulation:

"Software-aided adjunctive diagnostic devices for use on skin lesions by physicians"

This new naming convention is significant. It explicitly frames these tools as adjunctive — designed to assist trained physicians, not replace clinical judgment — and specifically calls out the software-aided nature of modern melanoma detection technology. This framing has direct implications for labeling, indications for use, and special controls compliance.

---

What Changed: A Side-by-Side Regulatory Comparison

Regulatory Element	Before (Class III)	After (Class II)
Premarket Pathway	Premarket Approval (PMA)	Premarket Notification (510(k))
Risk Classification	Highest Risk	Moderate Risk
Product Codes	OYD, ONV	OYD, ONV (retained, reclassified)
Classification Name	Optical diagnostic device for melanoma detection / Electrical impedance spectrometer	Software-aided adjunctive diagnostic devices for use on skin lesions by physicians
Special Controls	N/A (PMA replaces special controls)	Yes — FDA-specified performance and labeling requirements
General Controls	Applies	Applies
Predicate Device Required?	No (PMA pathway)	Yes (510(k) substantial equivalence)
Average Pathway Timeline	3–5 years	12–18 months (typical 510(k))
Clinical Data Requirements	Extensive pivotal trials (PMA-level)	Performance testing per special controls

This is a meaningful reduction in regulatory burden — but it is not a deregulatory free-for-all. Class II special controls exist precisely because FDA determined that general controls alone are insufficient to provide reasonable assurance of safety and effectiveness. Manufacturers must fully understand and comply with those special controls to bring a 510(k) to clearance.

---

The Special Controls Framework: What Manufacturers Must Meet

Special controls under Class II reclassification orders are legally binding. For software-aided adjunctive diagnostic devices for skin lesions, expect FDA's special controls to address some combination of the following (consistent with FDA's approach to similar AI/ML-assisted diagnostic devices):

1. Device-Specific Performance Testing

Manufacturers will need to demonstrate clinically meaningful sensitivity and specificity for melanoma detection against a validated reference standard (typically biopsy-confirmed pathology). FDA has signaled that performance benchmarks — not just technical testing — are required.

2. Software Documentation Requirements

Given the "software-aided" framing, expect rigorous software lifecycle documentation requirements consistent with FDA's guidance on Software as a Medical Device (SaMD) and the IEC 62304 software lifecycle standard. This includes: - Software description and architecture - Hazard analysis - Verification and validation (V&V) records - Cybersecurity risk documentation

3. Labeling Requirements

The "adjunctive" language in the new device name is not cosmetic — it must be reflected in labeling. Indications for use must clearly state that the device is intended to assist a trained physician, not to diagnose independently. Labeling must include: - Intended user qualifications (physician use only) - Limitations of the device - Instructions for interpreting device output in the clinical context

4. Clinical Performance Data

FDA will require clinical studies demonstrating the device's performance across diverse patient populations, including varying skin tones, lesion types, and clinical presentations — an area of growing regulatory scrutiny for AI-based diagnostic tools.

5. Post-Market Surveillance

Class II special controls may include requirements for post-market performance monitoring, particularly relevant for AI/ML systems that may drift in performance over time (a known challenge addressed in FDA's Predetermined Change Control Plan (PCCP) guidance).

---

Effective Dates, Timelines, and Compliance Deadlines

This is where practical compliance planning begins. Here is what manufacturers need to track:

• Federal Register Publication Date: March 25, 2026
• Final Order Effective Date: Typically 30 days after publication in the Federal Register (approximately April 24, 2026), unless otherwise specified in the order. Manufacturers should confirm the exact effective date in the published document at federalregister.gov/documents/2026/03/25/2026-05772.
• Transition for Existing Class III Devices: Manufacturers with devices currently on the market under IDE or PMA should consult with FDA about transitional provisions. Reclassification orders typically include provisions allowing marketed devices to continue while manufacturers submit 510(k)s.
• New Market Entrants: Devices entering the market after the effective date must submit a 510(k) premarket notification demonstrating substantial equivalence to a legally marketed predicate device within the new classification.

Citation hook: FDA's March 25, 2026 final order reclassifying melanoma detection devices from Class III to Class II under 21 CFR represents the first time software-aided adjunctive skin lesion diagnostic devices have been formally codified under a unified classification regulation.

---

Why FDA Made This Move: The Regulatory Rationale

FDA's decision to reclassify was driven by accumulated post-market performance data and the maturation of the technology landscape. Several key factors support the downclassification:

• Accumulated safety data: Years of real-world use of optical and impedance-based skin diagnostic tools have generated a substantial evidence base demonstrating a manageable risk profile when used as adjunctive tools by trained physicians.
• Defined special controls sufficiency: FDA determined that Class II special controls — combined with general controls — provide reasonable assurance of safety and effectiveness without requiring the full PMA burden. This is the legal standard for Class II under 21 U.S.C. § 360c(a)(1)(B).
• Technology maturation: The shift toward software-aided interpretation reflects the increasingly digital and algorithmic nature of these devices, aligning FDA's classification framework with modern product architectures.

According to the FDA's classification database, there are currently fewer than 10 legally marketed devices in the OYD and ONV categories — a relatively thin competitive landscape that this reclassification is likely to significantly expand by lowering barriers to entry.

Citation hook: FDA's reclassification under the final order published March 25, 2026 lowers the regulatory pathway for melanoma detection software from PMA to 510(k), a change that industry analysts project could reduce time-to-market by two to four years for qualifying devices.

---

The AI/ML Dimension: Why This Reclassification Has Broader Implications

The new classification name — "software-aided adjunctive diagnostic devices for use on skin lesions by physicians" — places this device type squarely in the fast-evolving regulatory conversation around artificial intelligence in medical devices.

As of early 2026, FDA has authorized more than 950 AI/ML-enabled medical devices, with dermatology being one of the most active development areas. Melanoma affects approximately 1 in 38 Americans over their lifetime, and early detection dramatically improves outcomes — 5-year survival rates for localized melanoma exceed 98%, compared to approximately 30% for distant-stage disease (American Cancer Society, 2025 data).

These statistics create enormous commercial pressure to develop and deploy AI-assisted diagnostic tools. The Class III barrier was suppressing innovation; Class II with appropriate special controls is a more proportionate risk framework for adjunctive physician tools.

However, manufacturers entering this space via 510(k) should be clear-eyed: the special controls for AI-based diagnostics are substantive and rigorous. FDA has increasingly scrutinized AI device submissions for algorithmic bias, demographic performance disparities, and post-market drift. A streamlined pathway does not mean a weak one.

Citation hook: Melanoma's five-year survival rate exceeds 98% when detected at the localized stage, making software-aided diagnostic adjuncts a clinically significant tool — and the FDA's reclassification of these devices to Class II reflects both the technology's maturation and its public health importance.

---

Practical Compliance Guidance: 6 Steps Manufacturers Should Take Now

Whether you are a current market participant or an emerging developer, here are the priority actions in the wake of this reclassification:

Step 1: Confirm Your Product Code and Classification Status

Determine whether your device falls under OYD, ONV, or the new unified classification. Review your device's indications for use against the new regulatory definition of "software-aided adjunctive diagnostic devices for use on skin lesions by physicians." If your device includes software-based interpretation of skin lesion imagery or impedance data for physician use, you are almost certainly in scope.

Step 2: Obtain and Study the Final Order and Special Controls

Download the full text of the final order from the Federal Register (Docket 2026-05772). Carefully map each special control requirement to your current technical documentation. Identify gaps between what you have and what FDA requires.

Step 3: Identify a 510(k) Predicate Device

Unlike PMA, 510(k) clearance requires demonstrating substantial equivalence to a legally marketed predicate device. Work with a qualified regulatory consultant to identify the strongest predicate(s) from the FDA's 510(k) database and build your equivalence argument around intended use, technological characteristics, and performance data.

Step 4: Scope Your Clinical and Performance Testing

Engage early with your clinical and biostatistics teams to design the performance studies FDA will expect. For AI/ML-based tools, this should include subgroup analyses across skin tones (Fitzpatrick scale) and lesion types, and you should document your validation dataset composition carefully.

Step 5: Review and Revise Your Labeling

Ensure your indications for use, contraindications, and user qualification statements reflect the adjunctive, physician-use framing required by the new classification. This is a common gap I see in early submissions — and FDA reviewers catch it quickly.

Step 6: Engage a Regulatory Expert Early

The 510(k) pathway is more accessible than PMA, but a poorly constructed submission still results in Additional Information (AI) requests and significant delays. Engaging an experienced FDA regulatory consultant at the pre-submission (Q-sub) stage — before you submit — is the highest-ROI step you can take. At Certify Consulting, I work with manufacturers of Class II medical devices to structure submissions that get cleared the first time.

For a broader look at how 510(k) submissions are structured and what FDA reviewers look for, see our guide on navigating FDA premarket notification requirements.

---

Frequently Asked Questions

What is the difference between a PMA and a 510(k) for melanoma detection devices?

A Premarket Approval (PMA) is FDA's most rigorous review pathway, previously required for Class III melanoma detection devices. It requires comprehensive clinical trials and often takes 3–5 years. A 510(k), now applicable after reclassification to Class II, requires demonstrating substantial equivalence to a predicate device and typically takes 12–18 months. The special controls framework compensates for the lower evidentiary bar by imposing specific performance and labeling requirements.

Does this reclassification affect devices already on the market?

Manufacturers with devices currently marketed under an approved PMA or an active IDE should review the transitional provisions in the final order. Generally, reclassification orders include provisions allowing existing marketed devices to remain on the market while manufacturers transition to the new 510(k) framework. Confirm the specific transition terms in FDA Docket 2026-05772.

What product codes are covered by this reclassification?

The reclassification covers product code OYD (optical diagnostic devices for melanoma detection) and product code ONV (electrical impedance spectrometers). Both are now codified under the new classification name "software-aided adjunctive diagnostic devices for use on skin lesions by physicians."

What are special controls, and are they legally binding?

Yes, special controls are legally binding requirements established by FDA to provide reasonable assurance of safety and effectiveness for Class II devices. They supplement the general controls that apply to all device classes (registration, listing, QSR, labeling, MDR). Special controls may include performance standards, post-market surveillance, patient registries, special labeling, or specific guidance documents.

Can an AI/ML-based skin lesion tool qualify under the new Class II classification?

Yes — in fact, the new classification name explicitly references "software-aided" devices, signaling that AI/ML-based tools are squarely within scope. However, manufacturers must address FDA's evolving expectations for algorithmic transparency, demographic performance data, and post-market monitoring. Consulting FDA's guidance on AI/ML-based SaMD is strongly recommended before submitting a 510(k) in this space.

---

The Bottom Line

FDA's reclassification of melanoma detection devices from Class III to Class II is a meaningful regulatory shift — one that opens a faster, more accessible pathway to market for optical and software-aided diagnostic tools while maintaining meaningful safety guardrails through special controls. For manufacturers who understand and navigate this framework well, the commercial opportunity is substantial. For those who underestimate the special controls requirements or rush a poorly prepared 510(k), the delays can still be costly.

With 200+ clients served and a 100% first-time audit pass rate, my team at Certify Consulting has the deep regulatory expertise to guide your device through this new pathway efficiently. Whether you're evaluating your current product code, building a 510(k) strategy, or preparing for a Q-sub meeting, we can help you move forward with confidence.

Ready to navigate the new Class II pathway for your skin lesion diagnostic device? Visit certify.consulting to schedule a consultation.

---

Last updated: 2026-04-05

Source: Federal Register, Vol. 91, March 25, 2026 — Docket No. 2026-05772. https://www.federalregister.gov/documents/2026/03/25/2026-05772